Morphotek
Exton · Founded 1999
About Morphotek
Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.
Company Facts
- Founded: 1999
- Legal name: Morphotek Inc.
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $78.5M
- Funding stage: M&A
- Last round: Grant (Oct 2010)
- Website: morphotek.com
- Phone: (610) 423-6100
Social Profiles
Canonical: https://fsome.com/organization/morphotek-8415583 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.